Company: CERO
Filing Date: 2025-01-21
Form Type: S-1/A
Source: 0001213900-25-004742
Chunk: 225

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-01-21
Form: S-1/A
Chunk 225
---
 contained herein may be different than you might obtain from other public companies. 141 MANAGEMENT OF CERO Executive Officers and Directors As of December 2, 2024, our directors and executive officers were as follows:

| Name                   |     | Age |     | Title                                |
| Executive Officers:    |     |     |     |                                      |
| Chris Ehrlich          |     |  54 |     | Chairman and Chief Executive Officer |
| Andrew “Al” Kucharchuk |     |  44 |     | Chief Financial Officer              |
| Kristen Pierce         |     |  54 |     | Chief Development Officer            |
| Directors:             |     |     |     |                                      |
| Brian G. Atwood        |     |  72 |     | Director                             |
| Michael Byrnes         |     |  48 |     | Director                             |
| Kathleen LaPorte       |     |  63 |     | Director                             |
| Lindsey Rolfe, M.D.    |     |  56 |     | Director                             |
| Shami Patel            |     |  55 |     | Director                             |

Executive Officers Chris Ehrlichhas served as our Chairman and Chief Executive Officer since December 2024. From October 2024 to November 2024, he served as the interim Chairman and Chief Executive Officer. Prior to this, he served as the Vice Chairman of our board of directors from February 2024 to October 2024. He previously served as the Chief Executive Officer of PBAX from October 2021 until the Closing of the Business Combination in February 2024. From January 2021 to August 2021, he served as the Chief Executive Officer of Locust Walk Acquisition Corp (Nasdaq: LWAC) until it merged with eFFECTOR Therapeutics, Inc. He is also the Principal of Ehrlich Bioventures, LLC, a consultancy working with emerging biopharma companies. He previously served as Senior Managing Director and the Global Head of Strategic Transactions at Locust Walk Partners from 2013 to 2021. He brings significant biotechnology industry, business development, venture capital experience, investment banking and SPAC experience. While at Locust Walk Partners, Mr. Ehrlich was involved with sourcing and leading multiple transactions for emerging biopharmaceutical companies, including the sale of Xyphos Biosciences, Inc. to Astellas in 2019 and the sale of Thar Pharmaceuticals to Gr